NO315931B1 - Vandig suspensjon av 9-hydroksyrisperidon-fettsyre estere - Google Patents
Vandig suspensjon av 9-hydroksyrisperidon-fettsyre estere Download PDFInfo
- Publication number
- NO315931B1 NO315931B1 NO19981984A NO981984A NO315931B1 NO 315931 B1 NO315931 B1 NO 315931B1 NO 19981984 A NO19981984 A NO 19981984A NO 981984 A NO981984 A NO 981984A NO 315931 B1 NO315931 B1 NO 315931B1
- Authority
- NO
- Norway
- Prior art keywords
- composition according
- active ingredient
- mixture
- agent
- stirring
- Prior art date
Links
- -1 fatty acid esters Chemical class 0.000 title claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 title claims description 4
- 239000000194 fatty acid Substances 0.000 title claims description 4
- 229930195729 fatty acid Natural products 0.000 title claims description 4
- 239000007900 aqueous suspension Substances 0.000 title description 13
- 239000000203 mixture Substances 0.000 claims description 73
- 238000009472 formulation Methods 0.000 claims description 38
- 239000004480 active ingredient Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000003755 preservative agent Substances 0.000 claims description 10
- 230000003542 behavioural effect Effects 0.000 claims description 9
- 239000000375 suspending agent Substances 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 8
- 239000000080 wetting agent Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 206010003805 Autism Diseases 0.000 claims description 4
- 208000020706 Autistic disease Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 206010026749 Mania Diseases 0.000 claims description 4
- 208000036626 Mental retardation Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- VOMKSBFLAZZBOW-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl hexadecanoate Chemical group FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)CCCC4OC(=O)CCCCCCCCCCCCCCC)=NOC2=C1 VOMKSBFLAZZBOW-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 23
- 229960001534 risperidone Drugs 0.000 description 22
- 150000002148 esters Chemical class 0.000 description 17
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 230000036470 plasma concentration Effects 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000008159 sesame oil Substances 0.000 description 7
- 235000011803 sesame oil Nutrition 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 208000027776 Extrapyramidal disease Diseases 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 229960004096 debrisoquine Drugs 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- JWPGJSVJDAJRLW-UHFFFAOYSA-N debrisoquin Chemical compound C1=CC=C2CN(C(=N)N)CCC2=C1 JWPGJSVJDAJRLW-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- ISYWECDDZWTKFF-UHFFFAOYSA-N n-nonadecanoic acid Natural products CCCCCCCCCCCCCCCCCCC(O)=O ISYWECDDZWTKFF-UHFFFAOYSA-N 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920006051 Capron® Polymers 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- NDJKXXJCMXVBJW-UHFFFAOYSA-N heptadecane Chemical compound CCCCCCCCCCCCCCCCC NDJKXXJCMXVBJW-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- YCOZIPAWZNQLMR-UHFFFAOYSA-N pentadecane Chemical compound CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- PDRBHXKNYZPKGI-UHFFFAOYSA-M silver phenylmercury acetate Chemical compound C(C)(=O)[O-].[Ag+].C1(=CC=CC=C1)[Hg] PDRBHXKNYZPKGI-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- IIYFAKIEWZDVMP-UHFFFAOYSA-N tridecane Chemical compound CCCCCCCCCCCCC IIYFAKIEWZDVMP-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96201429 | 1996-05-20 | ||
| PCT/EP1997/002504 WO1997044039A1 (en) | 1996-05-20 | 1997-05-12 | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO981984D0 NO981984D0 (no) | 1998-04-30 |
| NO981984L NO981984L (no) | 1998-11-19 |
| NO315931B1 true NO315931B1 (no) | 2003-11-17 |
Family
ID=8224016
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19981984A NO315931B1 (no) | 1996-05-20 | 1998-04-30 | Vandig suspensjon av 9-hydroksyrisperidon-fettsyre estere |
| NO2011015C NO2011015I2 (no) | 1996-05-20 | 2011-08-29 | Paliperidon palmitatester |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2011015C NO2011015I2 (no) | 1996-05-20 | 2011-08-29 | Paliperidon palmitatester |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6077843A (de) |
| EP (1) | EP0904081B1 (de) |
| JP (1) | JP3274687B2 (de) |
| KR (1) | KR100358373B1 (de) |
| CN (1) | CN1093762C (de) |
| AR (1) | AR007194A1 (de) |
| AT (1) | ATE208619T1 (de) |
| AU (1) | AU715572B2 (de) |
| BG (1) | BG62684B1 (de) |
| BR (1) | BR9706824B8 (de) |
| CA (1) | CA2236691C (de) |
| CY (2) | CY2270B1 (de) |
| CZ (1) | CZ291284B6 (de) |
| DE (2) | DE69708284T2 (de) |
| DK (1) | DK0904081T3 (de) |
| EA (1) | EA000536B1 (de) |
| EE (1) | EE03594B1 (de) |
| ES (1) | ES2167745T3 (de) |
| FR (1) | FR11C0035I2 (de) |
| HK (1) | HK1017852A1 (de) |
| HR (1) | HRP970276B1 (de) |
| HU (2) | HU224025B1 (de) |
| ID (1) | ID16927A (de) |
| IL (1) | IL124551A (de) |
| LU (1) | LU91842I2 (de) |
| MX (1) | MX9804816A (de) |
| MY (1) | MY126302A (de) |
| NO (2) | NO315931B1 (de) |
| NZ (1) | NZ330369A (de) |
| PL (1) | PL188309B1 (de) |
| PT (1) | PT904081E (de) |
| SI (1) | SI0904081T1 (de) |
| SK (1) | SK284013B6 (de) |
| TR (1) | TR199800923T2 (de) |
| TW (1) | TW487572B (de) |
| UA (1) | UA61898C2 (de) |
| WO (1) | WO1997044039A1 (de) |
| ZA (1) | ZA974331B (de) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA72189C2 (uk) * | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| EP1056443B1 (de) * | 1998-02-25 | 2004-05-06 | Abbott Laboratories | Butorphanol enthaltende formulierungen mit verzögerter freisetzung |
| US6342488B1 (en) | 1998-08-18 | 2002-01-29 | Sepracor, Inc. | Phosphonorisperidone and sulforisperidone compositions and methods |
| CA2371940C (en) | 1999-03-31 | 2008-07-15 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
| US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| HUP0302874A2 (hu) * | 2000-08-14 | 2003-12-29 | Teva Pharmaceutical Industries Ltd. | Eljárás risperidon előállítására |
| US7666445B2 (en) * | 2000-10-20 | 2010-02-23 | The Trustees Of The University Of Pennsylvania | Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use |
| GB0216416D0 (en) * | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| ATE373472T1 (de) * | 2002-07-29 | 2007-10-15 | Alza Corp | Verfahren und dosierformen für die kontrollierte abgabe von paliperidon |
| US20050232995A1 (en) * | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| GB0322994D0 (en) * | 2003-10-01 | 2003-11-05 | Novartis Ag | Organic compounds |
| PT1675573E (pt) | 2003-10-23 | 2008-12-30 | Otsuka Pharma Co Ltd | Formulação de iripiprazole injectável estéril de libertação controlada e um processo para a sua preparação |
| US8221778B2 (en) * | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| EP2633853A1 (de) * | 2004-01-12 | 2013-09-04 | The Trustees of The University of Pennsylvania | Langzeitabgabe von Lieferungsformulierungen und Verwendungsverfahren dafür |
| US8329203B2 (en) * | 2004-01-12 | 2012-12-11 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| ES2245252B1 (es) * | 2004-06-15 | 2007-03-01 | Farmalider, S.A. | Solucion acuosa de risperidona para administracion oral. |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| JP5249748B2 (ja) | 2005-04-25 | 2013-07-31 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 無菌３−［２−［４−（６−フルオロ−１，２−ベンズイソオキサゾール−３−イル）−１−ピペリジニル］エチル］−６，７，８，９−テトラヒドロ−９−ヒドロキシ−２−メチル−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンパルミチン酸エステルの製造 |
| PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
| NZ574524A (en) | 2006-08-09 | 2011-07-29 | Intarcia Therapeutics Inc | Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring |
| US8314110B2 (en) * | 2007-04-19 | 2012-11-20 | Youxin Li | Compounds for treating mental disorders, and preparation and uses thereof |
| EP2157967B1 (de) | 2007-04-23 | 2013-01-16 | Intarcia Therapeutics, Inc | Suspensionsformulierungen insulinotroper peptide und ihre verwendung |
| US20090076035A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched paliperidone |
| KR20100099292A (ko) * | 2007-12-19 | 2010-09-10 | 얀센 파마슈티카 엔.브이. | 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법 |
| US20090209757A1 (en) * | 2008-01-10 | 2009-08-20 | Santiago Ini | Processes for the preparation and purification of paliperidone palmitate |
| WO2009102467A2 (en) | 2008-02-13 | 2009-08-20 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| KR101760953B1 (ko) | 2008-09-04 | 2017-07-24 | 아밀린 파마슈티칼스, 엘엘씨. | 비-수성 담체를 이용한 서방성 제형물 |
| LT2462246T (lt) | 2009-09-28 | 2017-11-27 | Intarcia Therapeutics, Inc | Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas |
| EP2493473A1 (de) | 2009-10-30 | 2012-09-05 | Janssen Pharmaceutica NV | Dosierplan im zusammenhang mit langwirkenden injizierbaren paliperidonestern |
| WO2011074017A1 (en) * | 2009-12-17 | 2011-06-23 | Alkem Laboratories Ltd. | A novel process for the preparation of paliperidone |
| TWI577377B (zh) | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| JP5893616B2 (ja) | 2010-10-18 | 2016-03-23 | 大日本住友製薬株式会社 | 注射用徐放性製剤 |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| WO2012164582A1 (en) | 2011-05-31 | 2012-12-06 | Ramamohan Rao Davuluri | Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido[ 1, 2-a]-pyrimidin-4-one (paliperidone) and paliperidone palmitate. |
| WO2013046225A2 (en) * | 2011-08-10 | 2013-04-04 | Glenmark Generics Limited | Process for the preparation of paliperidone palmitate |
| CN102993200B (zh) * | 2011-09-10 | 2016-02-03 | 鲁翠涛 | 帕潘立酮氨基酸酯及其制备方法 |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| US10525057B2 (en) | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| MA41917B1 (fr) | 2015-04-07 | 2020-07-29 | Janssen Pharmaceuticals Inc | Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée |
| JP6993235B2 (ja) | 2015-06-03 | 2022-01-13 | インターシア セラピューティクス，インコーポレイティド | インプラントの設置及び撤去システム |
| EP3458084B1 (de) | 2016-05-16 | 2020-04-01 | Intarcia Therapeutics, Inc | Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| KR20190104039A (ko) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법 |
| DK4025187T3 (da) | 2020-11-30 | 2024-03-04 | Janssen Pharmaceutica Nv | Doseringsregimer associeret med injicerbare paliperidonformuleringer med forlænget frigivelse |
| AU2021388842A1 (en) | 2020-11-30 | 2023-07-13 | Janssen Pharmaceutica Nv | Methods for ensuring resuspension of paliperidone palmitate formulations |
| CN116583270A (zh) | 2020-11-30 | 2023-08-11 | 詹森药业有限公司 | 与延长释放帕潘立酮可注射制剂相关的给药方案 |
| TW202222317A (zh) | 2020-11-30 | 2022-06-16 | 比利時商健生藥品公司 | 與延釋帕利哌酮可注射配製物相關之投藥方案（一） |
| HUP2100259A1 (hu) | 2021-07-07 | 2023-01-28 | Richter Gedeon Nyrt | Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények |
| IL310909A (en) | 2021-08-20 | 2024-04-01 | Janssen Pharmaceutica Nv | Dosing regimens associated with delayed-release injectable formulations of paliperidone |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2000786C (en) * | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
| US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| US5254556A (en) * | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
| TW376319B (en) * | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
| JPH09505308A (ja) * | 1993-11-19 | 1997-05-27 | アルカーミズ・コントロールド・セラピューティクス・インコーポレイテッド・トゥー | 生物学的活性剤を含有する生分解性微粒子の製造 |
| US5650173A (en) * | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
| ES2236700T3 (es) * | 1993-11-19 | 2005-07-16 | Janssen Pharmaceutica N.V. | 1,2-benzazoles microencapsulados. |
| ATE199147T1 (de) * | 1995-06-06 | 2001-02-15 | Aventis Pharma Inc | Benzisoxazol- und indazol- derivate als antipsychotika |
| US5792477A (en) * | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
-
1997
- 1997-05-01 TW TW086105768A patent/TW487572B/zh not_active IP Right Cessation
- 1997-05-12 TR TR1998/00923T patent/TR199800923T2/xx unknown
- 1997-05-12 CN CN97191494A patent/CN1093762C/zh not_active Expired - Lifetime
- 1997-05-12 CA CA002236691A patent/CA2236691C/en not_active Expired - Lifetime
- 1997-05-12 PT PT97923912T patent/PT904081E/pt unknown
- 1997-05-12 JP JP54150097A patent/JP3274687B2/ja not_active Expired - Lifetime
- 1997-05-12 EA EA199800531A patent/EA000536B1/ru not_active IP Right Cessation
- 1997-05-12 PL PL97327995A patent/PL188309B1/pl unknown
- 1997-05-12 DK DK97923912T patent/DK0904081T3/da active
- 1997-05-12 NZ NZ330369A patent/NZ330369A/xx not_active IP Right Cessation
- 1997-05-12 WO PCT/EP1997/002504 patent/WO1997044039A1/en active IP Right Grant
- 1997-05-12 DE DE69708284T patent/DE69708284T2/de not_active Expired - Lifetime
- 1997-05-12 US US09/180,659 patent/US6077843A/en not_active Expired - Lifetime
- 1997-05-12 AT AT97923912T patent/ATE208619T1/de active
- 1997-05-12 EP EP97923912A patent/EP0904081B1/de not_active Expired - Lifetime
- 1997-05-12 CZ CZ19981401A patent/CZ291284B6/cs not_active IP Right Cessation
- 1997-05-12 IL IL12455197A patent/IL124551A/xx not_active IP Right Cessation
- 1997-05-12 BR BRPI9706824-1B8A patent/BR9706824B8/pt not_active IP Right Cessation
- 1997-05-12 ES ES97923912T patent/ES2167745T3/es not_active Expired - Lifetime
- 1997-05-12 SK SK620-98A patent/SK284013B6/sk not_active IP Right Cessation
- 1997-05-12 SI SI9730272T patent/SI0904081T1/xx unknown
- 1997-05-12 AU AU29559/97A patent/AU715572B2/en not_active Expired
- 1997-05-12 DE DE201112100027 patent/DE122011100027I1/de active Pending
- 1997-05-12 HU HU9901319A patent/HU224025B1/hu active Protection Beyond IP Right Term
- 1997-05-12 EE EE9800136A patent/EE03594B1/xx active Protection Beyond IP Right Term
- 1997-05-12 KR KR10-1998-0703629A patent/KR100358373B1/ko active IP Right Review Request
- 1997-05-19 MY MYPI97002172A patent/MY126302A/en unknown
- 1997-05-19 ZA ZA974331A patent/ZA974331B/xx unknown
- 1997-05-19 ID IDP971649A patent/ID16927A/id unknown
- 1997-05-19 AR ARP970102112A patent/AR007194A1/es active IP Right Grant
- 1997-05-20 HR HR970276A patent/HRP970276B1/xx not_active IP Right Cessation
- 1997-12-05 UA UA98052747A patent/UA61898C2/uk unknown
-
1998
- 1998-04-30 NO NO19981984A patent/NO315931B1/no not_active IP Right Cessation
- 1998-05-12 BG BG102443A patent/BG62684B1/bg unknown
- 1998-06-15 MX MX9804816A patent/MX9804816A/es unknown
-
1999
- 1999-07-10 HK HK99102949A patent/HK1017852A1/xx not_active IP Right Cessation
-
2002
- 2002-04-25 CY CY0200021A patent/CY2270B1/xx unknown
-
2011
- 2011-07-20 LU LU91842C patent/LU91842I2/fr unknown
- 2011-08-18 HU HUS1100013C patent/HUS1100013I1/hu unknown
- 2011-08-18 CY CY2011011C patent/CY2011011I2/el unknown
- 2011-08-29 NO NO2011015C patent/NO2011015I2/no unknown
- 2011-09-02 FR FR11C0035C patent/FR11C0035I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO315931B1 (no) | Vandig suspensjon av 9-hydroksyrisperidon-fettsyre estere | |
| US10736842B2 (en) | Pharmaceutical oil-in-water nano-emulsion | |
| EP1575585B1 (de) | Flüssige pharmazeutische zusammensetzung mit pyridonderivaten | |
| NO339802B1 (no) | Formulering for nasal anvendelse omfattende neurotransmittere | |
| US20100041624A1 (en) | Buprenorphine formulations for intranasal delivery | |
| CN1129400A (zh) | 维生素e生育酚衍生物在眼科组合物中的应用 | |
| NO320384B1 (no) | Farmasoytisk sammensetning egnet som depot-formulering omfattende en dispersjon av mikropartikkelformede 9-hydroksyrisperidon-fettsyreestere samt deres anvendelse | |
| EP1754491A1 (de) | Ophthalmische perkutan absorbierte zubereitung mit muscarin-rezeptor-agonist | |
| AU2001291775B2 (en) | Testosterone ester formulation for human use | |
| WO2006132342A1 (ja) | ロフルミラスト点眼液 | |
| AU2001291775A1 (en) | Testosterone ester formulation for human use | |
| KR20040018380A (ko) | 피렌제핀 안약 겔제 | |
| WO2006018997A1 (ja) | 外用剤 | |
| TWI707684B (zh) | 點眼用懸濁製劑 | |
| WO2019171260A1 (en) | Pharmaceutical composition of lifitegrast | |
| US11400048B2 (en) | Pharmaceutical oil-in-water nano-emulsion | |
| EP3760206A1 (de) | Wässriges suspensionsartiges pharmazeutisches präparat mit kontrollierter auflösung | |
| WO2024062443A1 (en) | Pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: XEPLION; NAT. REG. NO/DATE: EU/1/11/672/001/NO 20110304; FIRST REG. NO/DATE: EU/1/11/672/001-006 20110304 Spc suppl protection certif: 2011015 Filing date: 20110829 |
|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: XEPLION; NAT. REG. NO/DATE: EU/1/11/672/001/NO 20110304; FIRST REG. NO/DATE: EU/1/11/672/001-006 20110304 Spc suppl protection certif: 2011015 Filing date: 20110829 Extension date: 20220512 |
|
| MK1K | Patent expired | ||
| SPCX | Expiry of an spc |
Spc suppl protection certif: 2011015 |